GRAL vs WST
GRAIL Inc. vs West Pharmaceutical Services — AI-powered side-by-side comparison
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | GRAL | WST |
|---|
| AI Score |
64
|
74
|
| Price |
$75.48
|
$351.74
|
| P/E Ratio |
-7.74×
|
44.65×
|
| ROE |
-15.8%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
-10.8%
|
36.8%
|
| Debt / Equity |
0.04×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
60.4
|
58.0
|
| Beta |
3.246
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for GRAL versus WST.
WST leads by 10 points.
WST scores 74/100 (Buy) versus GRAL at 64/100 (Buy).
GRAL Committee View
67% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is bollinger bandwidth of 20.8% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -16.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 20.8% signals elevated volatility — Risk
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical